JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2007; 49:1982-1988, doi:10.1016/j.jacc.2007.03.025 (Published online 10 April 2007).
© 2007 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow View Appendix
Right arrow All Versions of this Article:
j.jacc.2007.03.025v1
49/19/1982    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (35)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bhatt, D. L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Bhatt, D. L.

EXPEDITED REVIEW

Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial

Deepak L. Bhatt, MD, FACC*,*, Marcus D. Flather, MD{dagger}, Werner Hacke, MD{ddagger}, Peter B. Berger, MD, FACC§, Henry R. Black, MD||, William E. Boden, MD, FACC, Patrice Cacoub, MD#, Eric A. Cohen, MD**, Mark A. Creager, MD, FACC{dagger}{dagger}, J. Donald Easton, MD{ddagger}{ddagger}, Christian W. Hamm, MD, FACC§§, Graeme J. Hankey, MD||||, S. Claiborne Johnston, MD, PhD¶¶, Koon-Hou Mak, MD, FACC##, Jean-Louis Mas, MD***, Gilles Montalescot, MD, PhD{dagger}{dagger}{dagger}, Thomas A. Pearson, MD, FACC{ddagger}{ddagger}{ddagger}, P. Gabriel Steg, MD, FACC§§§, Steven R. Steinhubl, MD, FACC||||||, Michael A. Weber, MD, FACC¶¶¶, Liz Fabry-Ribaudo, MSN, RN*, Tingfei Hu, MS*, Eric J. Topol, MD, FACC###, Keith A.A. Fox, MBChB**** for the CHARISMA Investigators

* Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio
{dagger} Clinical Trials and Evaluation Unit, Royal Brompton Hospital, London, United Kingdom
{ddagger} Department of Neurology, University of Heidelberg, Heidelberg, Germany
§ Geisinger Center for Health Research, Danville, Pennsylvania
|| New York University School of Medicine, New York, New York
Division of Cardiology, Kaleida Healthcare, Buffalo, New York
# Department of Internal Medicine, Hopital Pitie-Salpetriere, Paris, France
** Division of Cardiology, Sunnybrook and Women’s College Health Science Centre, Toronto, Canada
{dagger}{dagger} Division of Cardiovascular Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
{ddagger}{ddagger} Department of Neurology, Rhode Island Hospital and Brown University, Providence, Rhode Island
§§ Department of Cardiology, Kerckhoff-Klinik Center, Bad Nauheim, Germany
|||| Department of Neurology, Royal Perth Hospital and School of Medicine and Pharmacology, The University of Western Australia, Perth, Australia
¶¶ Department of Neurology, University of California San Francisco, San Francisco, California
## Gleneagles Medical Centre, Singapore
*** Department of Neurology and Stroke Unit, Sainte-Anne Hospital, Paris, France
{dagger}{dagger}{dagger} Institut de Cardiologie — Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris, France
{ddagger}{ddagger}{ddagger} Department of Community & Preventive Medicine, University of Rochester School of Medicine, Rochester, New York
§§§ Service de Cardiologie, Hôpital Bichat, Paris, France
|||||| Division of Cardiology, University of Kentucky, Lexington, Kentucky
¶¶¶ SUNY Downstate Medical Center College of Medicine, Brooklyn, New York
### Case Western Reserve University, Cleveland, Ohio
**** University and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom.

Manuscript received December 4, 2006; revised manuscript received March 16, 2007, accepted March 20, 2007.

* Reprint requests and correspondence: Dr. Deepak L. Bhatt, Associate Director, Cardiovascular Coordinating Center, Staff, Cardiac, Peripheral, and Carotid Intervention, Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Avenue, Desk F25, Cleveland, Ohio 44195. (Email: bhattd{at}ccf.org).

Objectives: The purpose of this study was to determine the possible benefit of dual antiplatelet therapy in patients with prior myocardial infarction (MI), ischemic stroke, or symptomatic peripheral arterial disease (PAD).

Background: Dual antiplatelet therapy with clopidogrel plus aspirin has been validated in the settings of acute coronary syndromes and coronary stenting. The value of this combination was recently evaluated in the CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance) trial, where no statistically significant benefit was found in the overall broad population of stable patients studied.

Methods: We identified the subgroup in the CHARISMA trial who were enrolled with documented prior MI, ischemic stroke, or symptomatic PAD.

Results: A total of 9,478 patients met the inclusion criteria for this analysis. The median duration of follow-up was 27.6 months. The rate of cardiovascular death, MI, or stroke was significantly lower in the clopidogrel plus aspirin arm than in the placebo plus aspirin arm: 7.3% versus 8.8% (hazard ratio [HR] 0.83, 95% confidence interval [CI] 0.72 to 0.96, p = 0.01). Additionally, hospitalizations for ischemia were significantly decreased, 11.4% versus 13.2% (HR 0.86, 95% CI 0.76 to 0.96, p = 0.008). There was no significant difference in the rate of severe bleeding: 1.7% versus 1.5% (HR 1.12, 95% CI 0.81 to 1.53, p = 0.50); moderate bleeding was significantly increased: 2.0% versus 1.3% (HR 1.60, 95% CI 1.16 to 2.20, p = 0.004).

Conclusions: In this analysis of the CHARISMA trial, the large number of patients with documented prior MI, ischemic stroke, or symptomatic PAD appeared to derive significant benefit from dual antiplatelet therapy with clopidogrel plus aspirin. Such patients may benefit from intensification of antithrombotic therapy beyond aspirin alone, a concept that future trials will need to validate. (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance [CHARISMA]; http://clinicaltrials.gov/ct/show/NCT00050817?order=1; NCT00050817 [ClinicalTrials.gov] )

Abbreviations and Acronyms
  CI = confidence interval
  HR = hazard ratio
  MI = myocardial infarction
  PAD = peripheral arterial disease




This article has been cited by other articles:


Home page
Am J Health Syst PharmHome page
J. Sullivan and N. Amarshi
Dual antiplatelet therapy with clopidogrel and aspirin
Am. J. Health Syst. Pharm., June 15, 2008; 65(12): 1134 - 1143.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
R. C. Becker, T. W. Meade, P. B. Berger, M. Ezekowitz, C. M. O'Connor, D. A. Vorchheimer, G. H. Guyatt, D. B. Mark, and R. A. Harrington
The Primary and Secondary Prevention of Coronary Artery Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest, June 1, 2008; 133(6_suppl): 776S - 814S.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. Y. Gasparyan, T. Watson, and G. Y.H. Lip
The Role of Aspirin in Cardiovascular Prevention: Implications of Aspirin Resistance
J. Am. Coll. Cardiol., May 13, 2008; 51(19): 1829 - 1843.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
V. Thijs, R. Lemmens, and S. Fieuws
Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens after transient ischaemic attack or stroke
Eur. Heart J., May 1, 2008; 29(9): 1086 - 1092.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
M. J. O'Donnell, G. J. Hankey, and J. W. Eikelboom
Antiplatelet Therapy for Secondary Prevention of Noncardioembolic Ischemic Stroke: A Critical Review
Stroke, May 1, 2008; 39(5): 1638 - 1646.
[Abstract] [Full Text] [PDF]


Home page
Cleveland Clinic Journal of MedicineHome page
M. R. BAKHRU and D. L. BHATT
INTERPRETING THE CHARISMA STUDY: What is the role of dual antiplatelet therapy with clopidogrel and aspirin?
Cleveland Clinic Journal of Medicine, April 1, 2008; 75(4): 289 - 295.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. Sanz, P. R. Moreno, and V. Fuster
The year in atherothrombosis.
J. Am. Coll. Cardiol., March 4, 2008; 51(9): 944 - 955.
[Full Text] [PDF]


Home page
PERSPECT VASC SURG ENDOVASC THERHome page
C. M. Wittgen
Limb Ischemia: Medical Therapy Trial Update
Perspectives in Vascular Surgery and Endovascular Therapy, March 1, 2008; 20(1): 38 - 42.
[Abstract] [PDF]


Home page
J Clin PharmacolHome page
F. M. Gengo, M. Rainka, M. Robson, M. F. Gengo, A. Forrest, M. Hourihane, and V. Bates
Prevalence of Platelet Nonresponsiveness to Aspirin in Patients Treated for Secondary Stroke Prophylaxis and in Patients With Recurrent Ischemic Events
J. Clin. Pharmacol., March 1, 2008; 48(3): 335 - 343.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
D. L. Bhatt
Intensifying Platelet Inhibition -- Navigating between Scylla and Charybdis
N. Engl. J. Med., November 15, 2007; 357(20): 2078 - 2081.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. M. Gebel Jr.
The CAPRIE-Like Subgroups of CHARISMA: A CAPRIEciously Biased Analysis of an unCHARISMAtic Truth
J. Am. Coll. Cardiol., October 23, 2007; 50(17): 1704 - 1704.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
D. L. Bhatt, M. D. Flather, and on behalf of the CHARISMA Executive Committee and
Reply
J. Am. Coll. Cardiol., October 23, 2007; 50(17): 1704 - 1705.
[Full Text] [PDF]


Home page
Eur Heart JHome page
T. H. Wang, D. L. Bhatt, K. A.A. Fox, S. R. Steinhubl, D. M. Brennan, W. Hacke, K.-H. Mak, T. A. Pearson, W. E. Boden, P. G. Steg, et al.
An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial
Eur. Heart J., September 2, 2007; 28(18): 2200 - 2207.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. A. Bavry and D. L. Bhatt
Drug-Eluting Stents: Dual Antiplatelet Therapy for Every Survivor?
Circulation, August 14, 2007; 116(7): 696 - 699.
[Full Text] [PDF]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2007 by the American College of Cardiology Foundation.